NextGen ALL risk stratification gene panel- B-ALL, Bone Marrow
NextGen ALL Risk Stratification Gene Panel by NGS - B-ALL, EDTA Bone Marrow** Price
Brief Details
What is a NextGen ALL Risk Stratification Gene Panel?
The NextGen ALL Risk Stratification gene panel is an advanced genetic test that uses Next Generation Sequencing (NGS) technology to analyse specific genes in patients already diagnosed with B-cell acute lymphoblastic leukaemia (B-ALL). This comprehensive test examines both hotspot mutations and gene fusions that are crucial for understanding your specific type of leukaemia.
The test helps doctors classify your leukaemia into different risk categories and identify specific genetic changes that can guide personalised treatment decisions and predict how your cancer might respond to various therapies.
What Does the NextGen ALL Risk Stratification Gene Panel Measure?
This comprehensive genetic panel provides detailed molecular information about your B-ALL:
- Specific genetic mutations - Identifies changes in genes known to influence B-ALL behaviour and treatment response.
- Molecular subtypes - Classifies your leukaemia into distinct genetic categories for targeted treatment approaches.
- Risk stratification markers - Determines whether your leukaemia falls into low, standard, or high-risk categories.
- Therapeutic targets - Discovers genetic weaknesses that can be targeted with specific medications.
- Prognostic indicators - Provides information about the likely disease course and ALL leukaemia treatment outcomes.
NextGen ALL Risk Stratification Gene Panel: Who Needs It and Why It's Done
Who Needs a NextGen ALL Risk Stratification Gene Panel?
- Newly diagnosed ALL patients (both paediatric and adult) – To guide initial risk classification and therapy intensity
- Relapsed or refractory ALL cases – To identify targetable mutations or emerging resistant clones
- Patients with atypical presentation or ambiguous cytogenetic findings – To clarify risk and assist in treatment planning
Who should get a NextGen ALL Risk Stratification Gene Panel?
This specialised test is recommended for specific patient groups:
- Patients with confirmed B-ALL diagnosis - Both children and adults assessed and diagnosed through acute lymphoblastic leukaemia risk stratification.
- Relapsed B-ALL patients - Those whose leukaemia has returned after initial treatment.
- Patients requiring treatment planning - When doctors need genetic information to choose the most effective therapy based on your health condition.
- High-risk cases - Patients with aggressive disease features who may benefit from targeted treatments.
Why is a NextGen ALL Risk Stratification Gene Panel done?
This test guides personalised treatment decisions by classifying your leukaemia into specific risk categories, allowing doctors to tailor therapy intensity and select the most effective treatment approach for your unique genetic profile.
Importance of a NextGen ALL Risk Stratification Gene Panel
This genetic panel represents a significant advancement in personalised cancer care for B-ALL patients. Rather than using a standard treatment approach for all patients, this test allows doctors to understand the unique genetic characteristics of your leukaemia cells.
The test provides crucial information for accurate risk assessment, helping predict whether your cancer is likely to respond well to standard treatment or requires more intensive therapy. It identifies specific genetic targets that can be treated with newer, more precise medications, often resulting in better outcomes with fewer side effects compared to traditional chemotherapy.
For patients with high-risk genetic markers, the test can guide decisions about bone marrow transplantation or clinical trials with experimental treatments. It also helps monitor minimal residual disease, detecting small numbers of remaining cancer cells that could cause relapse, enabling early intervention when treatments are most effective.
NextGen ALL Risk Stratification Gene Panel Booking & Reports – Metropolis Healthcare India
How to Book a NextGen ALL Risk Stratification Gene Panel?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select NextGen ALL Risk Stratification Gene Panel- B-ALL, Bone Marrow, choose a convenient time slot, and visit the nearest Metropolis Lab.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is home sample collection for NextGen ALL Risk Stratification Gene Panel available near you?
No, Metropolis Healthcare does not provide home sample collection for the
NextGen ALL Risk Stratification Gene Panel test. This specialised test requires bone marrow sample collection, which must be performed in a clinical setting by trained medical professionals. Our experienced team will coordinate with your healthcare provider to ensure the bone marrow sample is collected safely and transported to our NABL & CAP accredited laboratories for accurate analysis.
How Long Does It Take to Get a NextGen ALL Risk Stratification Gene Panel- B-ALL, Bone Marrow Report?
Reports are usually available after 20 days once the sample reaches the lab.
Note: Reporting time may vary depending on your location.
Where can I see or get NextGen ALL Risk Stratification Gene Panel- B-ALL, Bone Marrow results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen ALL Risk Stratification Gene Panel Results
What Your NextGen ALL Risk Stratification Gene Panel- B-ALL, Bone Marrow Results May Indicate
Your genetic panel results provide detailed information about mutations found in your leukaemia cells and their clinical significance:
|
Parameters |
Normal/Favourable Result |
Abnormal/Unfavourable Result |
Clinical Significance |
|
KRAS Gene |
No mutations detected |
Mutations present (e.g., p.Gly13Asp) |
Mutations may indicate higher relapse risk and need for targeted therapy |
|
ABL1 Gene |
No mutations detected |
Mutations or fusions present |
May suggest the need for tyrosine kinase inhibitor therapy |
|
FLT3 Gene |
No mutations detected |
Mutations present |
Associated with treatment response and prognosis |
|
ETV6 Gene |
No fusions detected |
ETV6 fusions present |
Important for risk stratification and treatment planning |
|
TP53 Gene |
No mutations detected |
Mutations present |
Associated with treatment resistance and poor prognosis |
Conditions that May Affect NextGen ALL Risk Stratification Gene Panel- B-ALL, Bone Marrow Accuracy
Several factors can influence the accuracy of your genetic panel results:
- Sample quality - Insufficient bone marrow cells or degraded DNA can affect sequencing quality and coverage.
- Technical limitations - GC-rich regions and homopolymers may influence sequencing quality and variant detection.
- Clonal heterogeneity - Different cancer cell populations within the sample may show varying genetic profiles.
- Treatment effects - Previous chemotherapy or radiation may alter the genetic landscape of leukaemia cells.
- Sample contamination - Presence of normal cells or other biological material can dilute cancer cell DNA.
- Processing delays - Extended time between collection and processing may affect sample integrity.
How is a NextGen ALL Risk Stratification Gene Panel Done?
The genetic analysis requires a bone marrow sample collected through a specialised medical procedure:
- Patient positioning - You'll lie on your stomach or side while the collection site (usually the back of your hip bone) is cleaned and sterilised.
- Local anaesthesia - A numbing injection is given to minimise discomfort during the procedure.
- Bone marrow aspirate - A thin needle extracts liquid bone marrow containing cancer cells for analysis.
- Tissue biopsy - A slightly larger needle collects a small solid piece of bone marrow tissue.
- Sample processing - The bone marrow is sent to our advanced molecular pathology laboratory.
- DNA/RNA extraction - Genetic material is carefully isolated from the cancer cells.
- Next Generation Sequencing - Advanced NGS sequencing technology analyses the specific genes in the panel.
- Data analysis - Sophisticated software aligns sequences to the human genome and identifies genetic variants.
- Result interpretation - Expert pathologists review findings and prepare your comprehensive report.
How Should You Prepare for a NextGen ALL Risk Stratification Gene Panel- B-ALL, Bone Marrow?
Proper preparation ensures accurate results and your comfort during the procedure:
- Medical history - Provide a complete clinical history, medical prescription, and previous test reports to your doctor.
- Medication review - Inform your healthcare team about all medications, especially blood thinners, which may need temporary discontinuation.
- Fasting requirements - If sedation is planned for the bone marrow procedure, you may need to fast beforehand. Always follow the specific instructions provided by your doctor.
- Wear comfortable clothing - Choose loose-fitting clothes that allow easy access to the hip area.
- Arrange transportation - Arrange for someone to accompany you if sedation is used during the procedure.
Diseases that a NextGen ALL Risk Stratification Gene Panel- B-ALL, Bone Marrow Can Help Detect
This specialised panel provides crucial information for managing various aspects of B-ALL:
- B-cell acute lymphoblastic leukaemia subtypes - Identifies specific molecular categories like Philadelphia chromosome-positive ALL.
- High-risk leukaemia variants - Detects genetic markers associated with aggressive disease behaviour.
- Treatment-resistant forms - Identifies mutations linked to chemotherapy resistance.
- Relapse-prone subtypes - Discovers genetic factors that increase the risk of disease recurrence.
- Targetable mutations - Finds genetic changes that respond to specific targeted therapies.
- Minimal residual disease - Helps detect small numbers of remaining leukaemia cells after treatment.
NextGen ALL Risk Stratification Gene Panel- B-ALL, Bone Marrow/Packages that You Can Book With Metropolis Healthcare
Metropolis Healthcare offers comprehensive haematological malignancies testing options to support your leukaemia care:
|
Test/Package Name |
Purpose/Highlights |
|
Monitors minimal residual disease in T-cell acute lymphoblastic leukaemia patients. |
|
|
Comprehensive flow cytometry analysis for lymphoma diagnosis and monitoring |
|
|
Genetic analysis for inherited bone marrow failure conditions |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.